Drugs / ASKG315
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05509985 | Aug → Sep 2023 | cancer | AskGene Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05554666 | Oct 2022 → Dec 2023 | cancer | AskGene Pharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASKG315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05554666 ↗ |
| Route | Intravenous | “ASKG315 or ASKG315 combined with pembrolizumab will be administered once every 3 weeks by intravenous (IV) infusion.” NCT05509985 ↗ |